Sign In
Buy SDGR
$14.93
-0.0100 (-0.0669%)
At Close: Jun 03, 2026
Schrodinger: Unlocking The Potential Of Computer-Assisted Drug Discovery During Tough Times
08:28am, Tuesday, 24'th Jan 2023
Schrodinger has developed a software platform that uses advanced physics and machine learning methods to predict important aspects of molecules with high accuracy. Their platform can help find new dru
Schrodinger: Solving The Critical Need For AI/ML In The Biopharma Industry
11:46pm, Saturday, 21'st Jan 2023
SDGR's valuable segment is its software business which represents majority of the revenue. There is an increasing demand for AI/ML capabilities by biopharmaceutical companies.
Why These 7 Healthcare Stocks Could Soar in 2023
07:22am, Monday, 02'nd Jan 2023
With the healthcare sector poised to grow significantly in the coming years, healthcare stocks to buy present a fantastic opportunity for investors. Healthcare is something that everyone will need at
7 Drug Stocks That Will Soar in 2023
06:00am, Thursday, 22'nd Dec 2022
Choosing the best drug stocks to buy can be dicey because drug stocks have disadvantages and advantages. On the negative side, you often have to wait many years for promising drugs to prove themselves
Schrodinger: Upgrading My Rating Post The Recent Nimbus Deal
08:15am, Monday, 19'th Dec 2022
Schrodinger stock saw a good jump last week post Nimbus Takeda deal. In addition to immediate benefits, the deal also signals strong long-term prospects for the company's drug discovery collaboration
Schrödinger: A Strong Player In The Field Of Drug Development Technology
01:35am, Tuesday, 22'nd Nov 2022
Schrödinger's revenue is growing due to its consistent market share growth. The company's software platform is used by the company's multidisciplinary drug discovery team, and several biopharmaceutic
Schrödinger to Present at Piper Sandler 34th Annual Healthcare Conference
08:30am, Monday, 21'st Nov 2022
NEW YORK--( BUSINESS WIRE )--Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that management
Schrödinger to Present at Jefferies 13th Annual London Healthcare Conference
08:30am, Monday, 07'th Nov 2022
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced that management will participate in the Jefferies 13th Annual London Healthcare Conference in London, UK.
3 Hypergrowth Stocks That Will Make You a Millionaire by 2027
06:35pm, Friday, 04'th Nov 2022
During the current earnings season, a few of the companies whose stocks I own delivered great third-quarter results. These results, along with their other achievements, shows that the firms' technolog
Schrodinger, Inc. (SDGR) Reports Q3 Loss, Tops Revenue Estimates
06:52pm, Thursday, 03'rd Nov 2022
Schrodinger, Inc. (SDGR) delivered earnings and revenue surprises of 8.20% and 14.37%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Schrödinger To Present New Preclinical Data From Its CDC7 Inhibitor Program At American Society Of Hematology 2022 Annual Meeting
09:23am, Thursday, 03'rd Nov 2022
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that new pre
Schrödinger to Announce Third Quarter 2022 Financial Results on November 3
08:30am, Thursday, 20'th Oct 2022
NEW YORK--(BUSINESS WIRE)---- $SDGR--Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, will report its third qu
7 Small-Cap Stock Picks to Beat the September Market Slump
06:30am, Thursday, 15'th Sep 2022
When compiling my small-cap stock picks, I tried to choose names that seemed to be benefiting from this new, more “risk-on” environment. Among the encouraging features of the August Consumer Price
Schrödinger: Q2 Earnings Supports Growth Narrative
05:40am, Friday, 26'th Aug 2022
Schrödinger reported mixed Q2 earnings with a miss on EPS and a beat on revenue. The company experienced strong performance across both aspects of the company business. The company revealed another q
Schrodinger, Inc. (SDGR) CEO Ramy Farid on Q2 2022 Results - Earnings Call Transcript
08:31pm, Thursday, 04'th Aug 2022
Schrodinger, Inc. (NASDAQ:SDGR ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Jaren Madden - SVP, IR & Corporate Communications Ramy Farid - CEO, President & Directo
